$1.13+$0.0100 (+0.89%) on the dayAs of the close; data may be delayed.
TLPH price, last 12 months
$1.47$0.7223$1.13
Daily closes over the last 260 trading sessions: +21.5%. Highest close $1.47 on , lowest $0.7223 on . Market data may be delayed.
Key stats
Previous close
$1.12
Open
$1.11
Day range
$1.09 – $1.14
52-week range
$0.6866 – $1.57
Volume
345.1K
Avg volume (20 days)
127.7K
Market cap
$60.2M
Performance
1W−4.2%
1M−5.8%
3M−4.2%
6M+56.4%
YTD−0.9%
1Y+21.1%
vs S&P 500, 1Y+5.9 pts
Technicals and fundamentals
About Talphera, Inc.
Talphera Inc. is a pharmaceutical company focused on the development and commercialization of therapies for use in medically supervised settings. The Company's nafamostat product candidates include Niyad and LTX-608. Its portfolio consists of nafamostat product candidates and pre-filled syringe product candidates.
Chart TLPH with indicators, scan for setups and get alerts
This page is open to everyone. A free ScanPro account adds the interactive parts, along with watchlists, paper trading with simulated money and the Academy's quizzes.
A full TLPH chart with indicator overlays, pattern markers and daily, weekly or intraday bars.
Scans of a whole index or list with 72 named conditions, 24 chart setups or a formula of your own.
Alerts and notifications when one fires on a stock you watch, on delayed market data.
Daily range (ATR)3.8%average true range, % of price
52w low $0.686652w high $1.57
Where price sits today against its own history. A description, not a forecast.
Valuation
P/E (trailing)—
P/E (forward)−5.3
PEG—
Price / sales61,508.37
Price / book3.20
EV / EBITDA—
Company figures as of Sep 25, 2026.
Analysts
Consensus—— on 1 (strong buy) to 5 (strong sell)
Analysts4
Average target$3.12+176.6% from today
Price targets are opinions and tend to lean optimistic. Only 4 analysts cover it, so one view moves the average.
Earnings
Quarter ended
EPS
YoY
Revenue
YoY
Jun '26
−0.06
—
$0
—
Mar '26
−0.04
—
$0
−100%
Dec '25
−0.03
—
$0
—
Sep '25
−0.11
—
$1K
—
Jun '25
−0.10
—
$0
—
Mar '25
−0.10
—
$27K
—
Dec '24
−0.07
—
$0
—
Sep '24
−0.13
—
$0
—
By the quarter each report covers, against the same quarter a year earlier. Growth from a loss is left blank: a percentage there reads backwards.
Seasonality
+2.5
J
+4.8
F
-17.9
M
+6.9
A
-3.3
M
+2.1
J
+8.8
J
+9.1
A
+15.0
S
+29.8
O
-12.7
N
-20.1
D
Average return in each calendar month, Feb 29, 2024 to Sep 30, 2026. 3 years is 3 observations a month: too few to call a pattern, so read it as history, not a calendar to trade.
Financials
As reported in the company's SEC filings. Latest: Q2 FY2026, ended Jun 30, 2026.
Figures are as each 10-Q and 10-K reported them, in the company's own fiscal calendar, not restated later. A company that changes how it reports a line can make one period look out of step with the rest. Growth compares the same period a year earlier and is left blank when the year before was a loss. Banks and insurers report no gross profit, so rows they don't file are left out. Every filing on SEC EDGAR
News
No recent news stored for this stock.
Tone is the news provider's automated reading of each article for this stock. It describes the article, not what the price will do.
Figures describe the past, not what the price will do next. Educational tools, not investment advice.